Inhibition of DDR1 ‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
EMBO Molecular Medicine, EarlyView. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - February 9, 2018 Category: Molecular Biology Source Type: research
---
EMBO Molecular Medicine, Ahead of Print. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - February 9, 2018 Category: Molecular Biology Source Type: research
Identification of potential therapeutic targets in prostate cancer through a cross ‐species approach
EMBO Molecular Medicine,Volume 10, Issue 3, March 2018. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - February 5, 2018 Category: Molecular Biology Source Type: research
---
EMBO Molecular Medicine,Volume 10, Issue 3, March 2018. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - February 5, 2018 Category: Molecular Biology Source Type: research
Trio sequencing in pediatric cancer and clinical implications
In pediatric cancer, we advocate for trio sequencing of the child and its parents. This method can have substantial implications for cancer prevention in parents and siblings and even in more distant family members. It does not only help to identify a putative classical cancer predisposition syndrome in the index patient, but also detects the combinatorial effect of two independent risk variants in the same signaling pathway. This type of inheritance pattern could contribute to explaining the early occurrence of cancer in children and young adults and thereby inform early diagnosis, screening and preventive measures.
From...
Source: EMBO Molecular Medicine - February 1, 2018 Category: Molecular Biology Authors: Michaela Kuhlen, Arndt Borkhardt Tags: Commentary Source Type: research
An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy
This study identifies a novel inhibitor against the MtArgJ enzyme of the arginine biosynthesis pathway, essential for pathogenicity and survival, and establishes its efficacy in pre‐clinical models. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - February 1, 2018 Category: Molecular Biology Authors: Archita Mishra, Ashalatha S Mamidi, Raju S Rajmani, Ananya Ray, Rajanya Roy, Avadhesha Surolia Tags: Research Article Source Type: research
Counteracting the effects of TNF receptor ‐1 has therapeutic potential in Alzheimer's disease
Abstract
Alzheimer's disease (AD) is the most common form of dementia, and neuroinflammation is an important hallmark of the pathogenesis. Tumor necrosis factor (TNF) might be detrimental in AD, though the results coming from clinical trials on anti‐TNF inhibitors are inconclusive. TNFR1, one of the TNF signaling receptors, contributes to the pathogenesis of AD by mediating neuronal cell death. The blood–cerebrospinal fluid (CSF) barrier consists of a monolayer of choroid plexus epithelial (CPE) cells, and AD is associated with changes in CPE cell morphology. Here, we report that TNF is the main inflammatory upstream m...
Source: EMBO Molecular Medicine - February 1, 2018 Category: Molecular Biology Authors: Sophie Steeland, Nina Gorl é, Charysse Vandendriessche, Sriram Balusu, Marjana Brkic, Caroline Van Cauwenberghe, Griet Van Imschoot, Elien Van Wonterghem, Riet De Rycke, Anneke Kremer, Saskia Lippens, Edward Stopa, Conrad E Johanson, Claude Libert, Roosm Tags: Research Article Source Type: research
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
Abstract
FGFR3 alterations (mutations or translocation) are among the most frequent genetic events in bladder carcinoma. They lead to an aberrant activation of FGFR3 signaling, conferring an oncogenic dependence, which we studied here. We discovered a positive feedback loop, in which the activation of p38 and AKT downstream from the altered FGFR3 upregulates MYC mRNA levels and stabilizes MYC protein, respectively, leading to the accumulation of MYC, which directly upregulates FGFR3 expression by binding to active enhancers upstream from FGFR3. Disruption of this FGFR3/MYC loop in bladder cancer cell lines by treatment wit...
Source: EMBO Molecular Medicine - February 1, 2018 Category: Molecular Biology Authors: M élanie Mahe, Florent Dufour, Hélène Neyret‐Kahn, Aura Moreno‐Vega, Claire Beraud, Mingjun Shi, Imene Hamaidi, Virginia Sanchez‐Quiles, Clementine Krucker, Marion Dorland‐Galliot, Elodie Chapeaublanc, Remy Nicolle, Hervé Lang, Celio Pouponnot Tags: Research Article Source Type: research
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non ‐small cell lung cancer
In this report, we describe a novel oncogenic signaling pathway exclusively acting in mutated epidermal growth factor receptor (EGFR) non‐small cell lung cancer (NSCLC) with acquired tyrosine kinase inhibitor (TKI) resistance. Mutated EGFR mediates TKI resistance through regulation of the fatty acid synthase (FASN), which produces 16‐C saturated fatty acid palmitate. Our work shows that the persistent signaling by mutated EGFR in TKI‐resistant tumor cells relies on EGFR palmitoylation and can be targeted by Orlistat, an FDA‐approved anti‐obesity drug. Inhibition of FASN with Orlistat induces EGFR ubiquitination a...
Source: EMBO Molecular Medicine - February 1, 2018 Category: Molecular Biology Authors: Azhar Ali, Elena Levantini, Jun Ting Teo, Julian Goggi, John G Clohessy, Chan Shuo Wu, Leilei Chen, Henry Yang, Indira Krishnan, Olivier Kocher, Junyan Zhang, Ross A Soo, Kishore Bhakoo, Tan Min Chin, Daniel G Tenen Tags: Research Article Source Type: research
Inhibition of DDR1 ‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
Abstract
The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. Here, we show that nilotinib, a clinically approved drug for chronic myeloid leukaemia, strongly inhibits human CRC cell invasion in vitro and reduces their metastatic potential in intrasplenic tumour mouse models. Nilotinib acts by inhibiting the kinase activity of DDR1, a receptor tyrosine kinase for collagens, which we identified as a RAS‐independent inducer of CRC metastasis. Using quantitative phosphoproteomics, we identified BCR as a new DDR1 substrate and demonstrated that nilotinib prevents DDR1‐mediated BCR phospho...
Source: EMBO Molecular Medicine - February 1, 2018 Category: Molecular Biology Authors: Maya Jeitany, C édric Leroy, Priscillia Tosti, Marie Lafitte, Jordy Le Guet, Valérie Simon, Debora Bonenfant, Bruno Robert, Fanny Grillet, Caroline Mollevi, Safia El Messaoudi, Amaëlle Otandault, Lucile Canterel‐Thouennon, Muriel Busson, Alain R Thie Tags: Research Article Source Type: research
miR ‐29 contributes to normal endothelial function and can restore it in cardiometabolic disorders
EMBO Molecular Medicine,Volume 10, Issue 3, March 2018. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - January 26, 2018 Category: Molecular Biology Source Type: research
---
EMBO Molecular Medicine,Volume 10, Issue 3, March 2018. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - January 26, 2018 Category: Molecular Biology Source Type: research
Dissecting human antibody responses: useful, basic and surprising findings
EMBO Molecular Medicine,Volume 10, Issue 3, March 2018. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - January 23, 2018 Category: Molecular Biology Source Type: research
Cell –cell signaling in blood vessel development and function
EMBO Molecular Medicine,Volume 10, Issue 3, March 2018. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - January 23, 2018 Category: Molecular Biology Source Type: research
---
EMBO Molecular Medicine,Volume 10, Issue 3, March 2018. (Source: EMBO Molecular Medicine)
Source: EMBO Molecular Medicine - January 23, 2018 Category: Molecular Biology Source Type: research
